和血明目片辅助治疗糖尿病性黄斑水肿气阴两虚夹瘀证22例临床观察  

Clinical observation on 22 cases of diabetic macular edema with deficiency of both qi and yin accompanied by blood stasis syndrome treated by Hexue Mingmu Pian(和血明目片)as adjuvant therapy

作　　者：沈丹青 王敏玲[1] 季晓燕[2] SHEN Danqing;WANG Minling;JI Xiaoyan(Department of Ophthalmology,Traditional Chinese Medicine Hospital of Taicang,Taicang,Jiangsu,215400,China;Department of Ophthalmology,the Second Hospital Affiliated to Suzhou University,Suzhou,Jiangsu,215000,China)

机构地区：[1]太仓市中医医院眼科,江苏太仓215400 [2]苏州大学附属第二医院眼科,江苏苏州215000

出　　处：《甘肃中医药大学学报》2021年第5期55-58,共4页Journal of Gansu University of Chinese Medicine

摘　　要：目的观察和血明目片辅助治疗糖尿病性黄斑水肿(DME)气阴两虚夹瘀证的临床疗效。方法将44例(57眼) DME气阴两虚夹瘀证患者采用随机数字表法分为对照组和治疗组,各22例。对照组给予玻璃体腔内注射康柏西普眼用注射液治疗,每月1次,并在注射康柏西普眼用注射液后1~2周内进行规范视网膜光凝术;治疗组在对照组治疗方法的基础上口服和血明目片,每次5片,每日3次。治疗3个月后比较2组不良反应发生率及治疗前,治疗后1周、1个月、3个月患者最佳矫正视力(BCVA)及黄斑中心凹视网膜厚度(CMT)。结果 2组治疗各时间段BCVA明显升高,CMT明显减小,与同组治疗前比较差异均有统计学意义(P<0.05),且治疗组改善更明显,治疗后3个月BCVA和各时间段CMT与同期对照组比较差异均有统计学意义(P<0.05)。2组不良反应发生率均为9.09%(2/22),2组比较差异无统计学意义(P>0.05)。结论和血明目片辅助治疗DME气阴两虚夹瘀证临床疗效显著,可改善BCVA,减轻黄斑水肿,且不良反应发生率低。Objective To observe the clinical efficacy of Hexue Mingmu Pian( 和血明目片) in adjuvant treatment of diabetic macular edema( DME) with deficiency of both qi and yin accompanied by blood stasis syndrome. Methods Forty-four cases( 57 eyes) of DME with deficiency of both qi and yin accompanied by blood stasis syndrome were divided into control group and treatment group according to random number table method,with 22 cases in each group. The control group was given intravitreal injection of conbercept ophthalmic injection once a month,and standard retinal photocoagulation was performed within 1-2 weeks after injection. On the basis of the therapeutic method of the control group,the treatment group was given oral administration of Hexue Mingmu Pian,5 tablets each time,3 times a day. After 3 months of treatment,the incidence of adverse reactions and the best corrected visual acuity( BCVA) and macular center thickness( CMT) of patients before treatment,at 1 week,1 month and 3 months after treatment were compared between the 2 groups. Results BCVA significantly increased and CMT significantly decreased in the 2 groups at each time period of treatment,and the differences were statistically significant compared with those of the same group before treatment( P<0.05),moreover,the improvement in the treatment group was more significant,and the differences were statistically significant compared between BCVA and CMT at each time period at 3 months after treatment and those of the control group at the same time period( P<0.05). The incidence of adverse reactions in both groups was 9.09%( 2/22),and there was no significant difference between the 2 groups( P>0.05). Conclusion It has marked clinical efficacy,can improve BCVA and alleviate macular edema with low incidence of adverse reactions to use Hexue Mingmu Pian in adjuvant treatment of DME with deficiency of both qi and yin accompanied by blood stasis syndrome.

关 键 词：糖尿病性黄斑水肿 气阴两虚夹瘀证 和血明目片 康柏西普 视网膜光凝术 临床疗效 

分 类 号：R276.745[医药卫生—中医五官科学]